These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 22564380)

  • 1. Activity landscape modeling of PPAR ligands with dual-activity difference maps.
    Méndez-Lucio O; Pérez-Villanueva J; Castillo R; Medina-Franco JL
    Bioorg Med Chem; 2012 Jun; 20(11):3523-32. PubMed ID: 22564380
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multitarget structure-activity relationships characterized by activity-difference maps and consensus similarity measure.
    Medina-Franco JL; Yongye AB; Pérez-Villanueva J; Houghten RA; Martínez-Mayorga K
    J Chem Inf Model; 2011 Sep; 51(9):2427-39. PubMed ID: 21842860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bioactivity landscape modeling: chemoinformatic characterization of structure-activity relationships of compounds tested across multiple targets.
    Waddell J; Medina-Franco JL
    Bioorg Med Chem; 2012 Sep; 20(18):5443-52. PubMed ID: 22178187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrated virtual screening for the identification of novel and selective peroxisome proliferator-activated receptor (PPAR) scaffolds.
    Nevin DK; Peters MB; Carta G; Fayne D; Lloyd DG
    J Med Chem; 2012 Jun; 55(11):4978-89. PubMed ID: 22582973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-activity relationships of dimeric PPAR agonists.
    Sauerberg P; Mogensen JP; Jeppesen L; Svensson LA; Fleckner J; Nehlin J; Wulff EM; Pettersson I
    Bioorg Med Chem Lett; 2005 Mar; 15(5):1497-500. PubMed ID: 15713415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sulfonylthiadiazoles with an unusual binding mode as partial dual peroxisome proliferator-activated receptor (PPAR) γ/δ agonists with high potency and in vivo efficacy.
    Keil S; Matter H; Schönafinger K; Glien M; Mathieu M; Marquette JP; Michot N; Haag-Diergarten S; Urmann M; Wendler W
    ChemMedChem; 2011 Apr; 6(4):633-53. PubMed ID: 21400663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of structurally constrained oxime-ether linker on PPAR subtype selectivity: Discovery of a novel and potent series of PPAR-pan agonists.
    Makadia P; Shah SR; Pingali H; Zaware P; Patel D; Pola S; Thube B; Priyadarshini P; Suthar D; Shah M; Giri S; Trivedi C; Jain M; Patel P; Bahekar R
    Bioorg Med Chem; 2011 Jan; 19(2):771-82. PubMed ID: 21215640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evolution of peroxisome proliferator-activated receptor agonists.
    Chang F; Jaber LA; Berlie HD; O'Connell MB
    Ann Pharmacother; 2007 Jun; 41(6):973-83. PubMed ID: 17519293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Indanylacetic acid derivatives carrying 4-thiazolyl-phenoxy tail groups, a new class of potent PPAR alpha/gamma/delta pan agonists: synthesis, structure-activity relationship, and in vivo efficacy.
    Rudolph J; Chen L; Majumdar D; Bullock WH; Burns M; Claus T; Dela Cruz FE; Daly M; Ehrgott FJ; Johnson JS; Livingston JN; Schoenleber RW; Shapiro J; Yang L; Tsutsumi M; Ma X
    J Med Chem; 2007 Mar; 50(5):984-1000. PubMed ID: 17274610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis, and evaluation of a novel series of alpha-substituted phenylpropanoic acid derivatives as human peroxisome proliferator-activated receptor (PPAR) alpha/delta dual agonists for the treatment of metabolic syndrome.
    Kasuga J; Yamasaki D; Araya Y; Nakagawa A; Makishima M; Doi T; Hashimoto Y; Miyachi H
    Bioorg Med Chem; 2006 Dec; 14(24):8405-14. PubMed ID: 16996742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 'Sum of activities' as dependent parameter: a new CoMFA-based approach for the design of pan PPAR agonists.
    Sundriyal S; Bharatam PV
    Eur J Med Chem; 2009 Jan; 44(1):42-53. PubMed ID: 18448203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual acting and pan-PPAR activators as potential anti-diabetic therapies.
    Heald M; Cawthorne MA
    Handb Exp Pharmacol; 2011; (203):35-51. PubMed ID: 21484566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rationalizing three-dimensional activity landscapes and the influence of molecular representations on landscape topology and the formation of activity cliffs.
    Peltason L; Iyer P; Bajorath J
    J Chem Inf Model; 2010 Jun; 50(6):1021-33. PubMed ID: 20443603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peroxisome proliferator-activated receptor alpha, delta, gamma1 and gamma2 expressions are present in human monocyte-derived dendritic cells and modulate dendritic cell maturation by addition of subtype-specific ligands.
    Jakobsen MA; Petersen RK; Kristiansen K; Lange M; Lillevang ST
    Scand J Immunol; 2006 May; 63(5):330-7. PubMed ID: 16640656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting components of the stress system as potential therapies for the metabolic syndrome: the peroxisome-proliferator-activated receptors.
    Yumuk VD
    Ann N Y Acad Sci; 2006 Nov; 1083():306-18. PubMed ID: 17148746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons.
    Tenenbaum A; Motro M; Fisman EZ
    Cardiovasc Diabetol; 2005 Sep; 4():14. PubMed ID: 16168052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Consensus models of activity landscapes with multiple chemical, conformer, and property representations.
    Yongye AB; Byler K; Santos R; Martínez-Mayorga K; Maggiora GM; Medina-Franco JL
    J Chem Inf Model; 2011 Jun; 51(6):1259-70. PubMed ID: 21609014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SAR-oriented discovery of peroxisome proliferator-activated receptor pan agonist with a 4-adamantylphenyl group as a hydrophobic tail.
    Kasuga J; Yamasaki D; Ogura K; Shimizu M; Sato M; Makishima M; Doi T; Hashimoto Y; Miyachi H
    Bioorg Med Chem Lett; 2008 Feb; 18(3):1110-5. PubMed ID: 18162399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis of new 8(S)-HETE analogs and their biological evaluation as activators of the PPAR nuclear receptors.
    Liutkus M; Caijo F; Girard AL; Ayral E; Audinot V; Boutin JA; Renard P; Caignard DH; Dacquet C; Ktorza A; Mosset P; Grée R
    J Enzyme Inhib Med Chem; 2010 Oct; 25(5):653-72. PubMed ID: 20518620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural basis for the structure-activity relationships of peroxisome proliferator-activated receptor agonists.
    Mahindroo N; Peng YH; Lin CH; Tan UK; Prakash E; Lien TW; Lu IL; Lee HJ; Hsu JT; Chen X; Liao CC; Lyu PC; Chao YS; Wu SY; Hsieh HP
    J Med Chem; 2006 Oct; 49(21):6421-4. PubMed ID: 17034149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.